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This daily COVID-19 Health Evidence Summary is to signpost DFID and other UK government 
departments to the latest relevant evidence and discourse on COVID-19 to inform and support 
their response. It is a result of 3 hours of work and is not intended to be a comprehensive summary 
of evidence. 
Palliative care and the COVID-19 pandemic 
The Lancet | 11 April 2020 | Editorial 
https://doi.org/10.1016/S0140-6736(20)30822-9 
The WHO has issued guidance on how to maintain essential services during the COVID-19 
pandemic but there has been no mention yet of palliative care. Palliative care should be an explicit 
part of national and international response plans for COVID-19 especially in low and middle-
income countries where shortages of both critical care and palliative care services are greatest. 
Where possible, practical steps can be taken to ensure access to drugs (such as opioids) and 
protective equipment, consider greater use of telemedicine and video, discuss advance care plans, 
provide better training and preparation across the health workforce, and embrace the role of lay 
carers and the wider community. 
COVID-19 and risks to the supply and quality of tests, drugs, and vaccines 
Newton et al. | The Lancet Global Health | 9 April 2020 | Comment 
https://doi.org/10.1016/S2214-109X(20)30136-4 
The COVID-19 pandemic threatens a global surge in substandard and falsified medical products, 
and not just for those directly related to COVID-19. Interventions are needed globally to ensure 
equitable access to safe, affordable, quality assured, and effective proven medical products to 
prevent, test or treat COVID-19. Supplies must not be hoarded or diverted from treatment of 
malaria, autoimmune diseases, or HIV/AIDS. ‘Bad tests will be worse than no tests.’ Robust 
policies and community-specific public engagement must guard against ineffective interventions, 
wasting resources and harm. 
Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed 
Feldmann et al. | The Lancet | 9 April 2020 | Comment 
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https://doi.org/10.1016/S0140-6736(20)30858-8 
‘Anti-TNF therapy should be evaluated in patients with COVID-19 on hospital admission to prevent 
progression to needing intensive care support’. There is evidence of an inflammatory excess in 
patients with COVID-19 with TNF, important in the coordination and development of the 
inflammatory response, found in blood and disease tissues of COVID-19 confirmed patients. 
Although there are many potential drug candidates for reducing inflammation in COVID-19, only a 
few are potentially effective, widely available and have a well-established safety profile – this 
includes the anti-TNF antibodies infliximab or adalimumab. 
Children’s story book released to help children and young people cope with COVID-19 
WHO | 9 April 2020 | News release of the Inter-Agency Standing Committee 
https://www.who.int/news-room/detail/09-04-2020-children-s-story-book-released-to-help-
children-and-young-people-cope-with-covid-19 
The COVID-19 vaccine development landscape 
Tung Thanh Le et al | Nature Reviews Drug Discovery | 9 April 2020 | From the analyst’s couch 
https://www.nature.com/articles/d41573-020-00073-5 
The Coalition for Epidemic Preparedness Innovations (CEPI) is working with global health 
authorities and vaccine developers to support the development of vaccines against COVID-19. 
They maintain an overview of the global landscape of COVID-19 vaccine development activity 
including vaccine development programmes reported through WHO’s continually updated list, 
along with other projects identified from publicly available sources. As of 8 April 2020, there are 
115 vaccines against COVID-19 in development. Seventy-eight are confirmed as active with a mix 
of 56 (72%) being developed by private/industry developers and 22 (28%) being led by academic, 
public sector and other non-profit organisations. Many of the lead developers are small and/or 
inexperienced in large-scale vaccine manufacture placing importance on coordination of vaccine 
manufacturing and supply capability and capacity to meet demand. There is currently no public 
information on vaccine development activity in Africa or Latin America and effective control of the 
pandemic will require greater coordination and involvement of the southern hemisphere in COVID-
19 vaccine R&D. 
A wide range of technology platforms are being assessed, including traditional and novel 
approaches which include DNA or mRNA and offer great flexibility in terms of antigen manipulation 
and potential for speed. Vaccines based on viral vectors offer a high level of protein expression 
and long-term stability and induce strong immune responses and already licensed vaccines based 
on recombinant proteins for other diseases could take advantage of existing large-scale production 
capacity. Adjuvants could enhance immunogenicity and make lower doses viable enabling 
vaccination of more people without compromising protection. Some vaccine developers have 
already committed to making licensed adjuvants available for use with novel COVID-19 vaccines 
developed by others. 
Strong international coordination and cooperation will be needed to ensure promising late-stage 
vaccine candidates can be manufactured in sufficient quantities and equitably suppled to all 
affected areas, particularly low-resource regions. 
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Compliance with physical distancing measures for COVID-19 and implications for RCCE 
in Eastern and Sothern Africa 
Anthrologica | Social Science in Humanitarian Action | April 2020 | Brief 
https://www.socialscienceinaction.org/resources/compliance-physical-distancing-measures-
covid-19-implications-rcce-eastern-southern-africa-april-2020/ 
This brief reports on attitudes and practices relating to physical distancing measures in the context 
of the COVID-19 outbreak across the Eastern and Southern African context. Practical 
recommendations are given for response partners communication strategies and messaging on 
physical distancing related to COVID-19 taking into account implementation challenges and 
mitigation of harmful effects. Where relevant, learnings from the Ebola outbreaks in West Africa 
and the DRC are applied. It was written on the request of UNICEF Eastern and Southern Africa 
Regional Office. 
A new survey on the risks of school closures for girls 
O’Donnell et al | Center for Global Development | 8 April 2020 | Survey 
https://www.cgdev.org/blog/new-survey-risks-school-closures-girls 
To better understand the challenges and perceptions of organisations delivering educational 
services to girls and boys in low-income countries, CGD have launched the Out of School Girls 
Survey to highlight some of the short and long-term gender-related concerns of those with first-
hand knowledge of the crisis is affected the girls and boys they serve. 
Risks and benefits of sustaining routine childhood immunisation programmes in Africa 
during the COVDID-19 pandemic 
Abbas et al| CMMID nCov working group | 7 April 2020 | Study (not yet peer reviewed) 
https://cmmid.github.io/topics/covid19/control-measures/EPI-suspension.html 
This study weighs the health benefits of continued routine infant immunisation delivery in Africa 
against the risk of acquiring coronavirus infections through visiting vaccination services. In 
sustaining routine childhood vaccination programmes for one excess COVID-19 death attributable 
to an infection acquired during a child vaccination visit, 128 (34-1247) future deaths in children 
from the time of vaccination to 5 years of age would be prevented. Limitations of the study are 
listed. 
WHO lists two COVID-19 tests for emergency use 
WHO | 7 April 2020 | Departmental news 
https://www.who.int/news-room/detail/07-04-2020-who-lists-two-covid-19-tests-for-emergency-
use 
The WHO has listed the first two diagnostic tests for emergency use during the COVID-19 
pandemic. This will help increase access to quality-assured tests for the disease and that the tests 
can now be supplied by the UN and other procurement agencies supporting the COVID-19 
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response. The in vitro diagnostic tests are genesig Real-Time PCR Coronavirus (COVID-19) 
(Primerdesign, UK) is an open system more suitable for laboratories with moderate sample testing 
capacity and cobas® SARS-CoV-2 Qualitative assay for use on the cobas 6800/8800 Systems 
(Roche, USA) is a closed system assay for larger laboratories. 
Tracking COVID-19 cases 
Global 
WHO COVID-19 daily situation reports 
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports 
Johns Hopkins University COVID-19 dashboard in real time 
https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467
b48e9ecf6 
WEF: Visualisation tracking confirmed cases of COVID-19 as it spreads. Updated daily. 
https://wef-prod.earthtime.org/m/stories/2019_nCOV_infection 
Vaccine Centre, LSHTM  
https://vac-lshtm.shinyapps.io/ncov_tracker/ 
This site complements the WHO and Johns Hopkins University COVID-19 dashboards by 
including the timeline functions, the ability to overlay past outbreaks, and an emphasis on 
normalised counts (per 100,000 individuals). 
Live data tracker: sex-disaggregated COVID-19 data from the 25 most-affected countries 
http://globalhealth5050.org/covid19 
Africa 
Coronavirus in Africa Tracker: How many covid-19 cases & where? 
https://africanarguments.org/2020/03/23/coronavirus-in-africa-tracker-how-many-cases-and-
where-latest/ 
UK 
PHE dashboard of UK COVID-19 Cases  
https://www.arcgis.com/apps/opsdashboard/index.html#/f94c3c90da5b4e9f9a0b19484dd4bb14 
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Tools 
WhatsApp coronavirus information hub 
https://www.whatsapp.com/coronavirus 
CMMID Repository: Effectiveness of airport screening at detecting travellers infected with 
COVID-19 
https://cmmid-lshtm.shinyapps.io/traveller_screening/ 
App to model effectiveness of airport screening. 
Disability Inclusive Community Action – COVID-19 Matrix 
CBM | 30 March 2020 | Tool 
https://www.cbm.org/news/news/news-2020/cbm-develops-disability-inclusive-community-action-
covid-19-matrix/ 
Online learning and events 
Online event: Policy modelling for COVID-19: Better data for better decision-making in low 
and middle-income countries 
Tuesday 14 April 2020 0900-1030 ET | Center for Global Development  
https://www.cgdev.org/event/policy-modelling-covid-19-better-data-better-decision-making-low-
and-middle-income-countries 
Moderator: Kalipso Chalkidou (CDG). Features Dan Ollendorf (CGD), Yot Teerawattananon 
(Thai Ministry of Public Health) and Anna Vassall (LSHTM) 
COVID-19 Diagnostics and Testing 
FIND, LSHTM & ASLM | FutureLearn course | Starts 20 April 2020 | 3 weeks | 3 hours weekly 
study | Free 
https://www.futurelearn.com/courses/covid-19-diagnostics-and-testing 
This course is designed for professionals involved in the testing and diagnosis of COVID-19, with 
a focus on low- and middle-income settings. You will learn the latest recommendations on COVID-
19 testing, get upt0date information on the performance of tests and how best to deploy them. 
COVID-19 Critical Care: Understanding and Application 
University of Edinburgh & Royal College of Physicians of Edinburgh  | FutureLearn course | 
Starts 6 April 2020 | 5 weeks | 1 hour weekly study | Free 
https://www.futurelearn.com/courses/covid-19-critical-care-education-resource 
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Designed for frontline clinical staff to learn the principles and practice of critical care to treat and 
care for critically ill patients during the COVID-19 pandemic. You will learn (1) how to apply the 
current and evolving principles of PPE in the care of COVID-19; (2) apply evidence-based 
principles of advanced organ support and monitoring to the COVID-19 critically ill patients; (3) 
apply evidence-based daily practices to care of the critically ill patient; and (4) develop a range of 
specialised self-caring practices. 
Note that this resource has been created in response to the COVID-19 emergency and does not 
correspond to the classic structure of a FutureLearn course. You do not have to follow the week 
by week approach and can select the materials most relevant to your work. 
Emerging respiratory viruses, including COVID-19: methods for detection, prevention, 
response and control 
WHO | Free | 3 hours duration  
https://openwho.org/courses/introduction-to-ncov 
A general introduction to enable you to describe the fundamental principles of emerging 
respiratory viruses, including novel coronaviruses, and how to effectively respond to an outbreak. 
Intended for public health professionals, incident managers and personnel working for the UN, 
international organisations and NGOs. 
Responding to COVID-19: Real-time training for the coronavirus disease outbreak 
WHO | Available now | multiple self-paced courses 
https://openwho.org/channels/covid-19 
Note that courses are available in English and other languages including French, Portuguese 
and Spanish. 
COVID-19: Tackling the Novel Coronavirus 
LSHTM | FutureLearn course | Starts 23 March 2020 | 3 weeks | 4 hours weekly study | Free 
https://www.futurelearn.com/courses/covid19-novel-coronavirus 
A reminder that this course is currently running. On this course you will learn what is known 
about the outbreak of COVID-19 (week 1); what the practical implications for responding to 
COVID-19 are (week 2); and what we need to find out about COVID-19 (week 3). 
Resource Hubs 
WHO: Coronavirus disease (COVID-19) pandemic 
https://www.who.int/emergencies/diseases/novel-coronavirus-2019 
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Resources on coronavirus and disability 
https://asksource.info/covid-resources/search 
ODI Coronavirus: latest research and analysis on the implications of the coronavirus 
pandemic worldwide 
https://www.odi.org/our-work/coronavirus 
International Disability and Development Consortium and CORE Group: Repository of 
resources on disability inclusion and COVID-19 
https://docs.google.com/document/d/1IVP1u6yHfLuN9qNyLEct5-vtC0aqLKtKr-o-faAjves/edit 
US NIH online platform of all registered, ongoing clinical trials globally 
https://clinicaltrials.gov/ct2/results?cond=COVID-19 
COVID-19 Narratives by Dr David Nabarro 
https://www.4sd.info/covid-19-narratives/ 
These narratives are being written by David Nabarro, Co-Director of the Imperial College Institute 
of Global Health Innovation at Imperial College London, Strategic Director for 4SD and one of six 
Special Envoys to the WHO DG Special Envoy on COVID-19, and peers to share with those who 
want more information about the situation and to help raise the awareness and readiness of all 
actors. Please visit WHO website for official guidance.  
Reliefweb COVID-19 
https://reliefweb.int/topics/covid-19 
Coronavirus global health emergency 
https://www.un.org/coronavirus 
Norwegian Institute of Public Health: Live map of COVID-19 evidence 
https://www.fhi.no/en/qk/systematic-reviews-hta/map/ 
Overview of scientific publications on COVID-19 categorised into subgroups to provide quick 
access to specific topic-relevant publications to help decision makers and research navigate the 
research and help identify research gaps.  
Vaccine Centre at LSHTM: COVID-19 vaccine development pipeline tracker 
https://vac-lshtm.shinyapps.io/ncov_vaccine_landscape/ 
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COVID-19 Research Project Tracker by UKCDR & GloPID-R 
https://www.ukcdr.org.uk/funding-landscape/covid-19-research-project-tracker/ 
A live database of funded research projects across the world related to COVID-19 mapped against 
the priorities identified in the WHO Coordination Global Research Roadmap: 2019 Novel 
Coronavirus. 
WHO Q&A on COVID-19 
https://www.who.int/news-room/q-a-detail/q-a-coronaviruses 
Note that this resource includes Q&A on COVID-19; COVID-19, pregnancy, childbirth and 
breastfeeding; COVID-19, HIV and antiretrovirals; similarities and differences COVID-19 and 
influenza; mass gatherings and COVID-19; IPC for healthcare workers; COVID-19 and food and 
agriculture; smoking and COVID-19; malaria and COVID-19. 
COVID-19: Resources and research on epidemics and pandemics 
https://steps-centre.org/covid-19-coronavirus-resources-research-epidemics-pandemics/ 
Stop TB Partnership TB and COVID-19 
http://www.stoptb.org/covid19.asp 
EPI-WIN: WHO information network for epidemics: COVID-19 public health emergency 
https://www.who.int/teams/risk-communication 
COVID-19: Research ethics 
https://ethicsresource.ringsgenderresearch.org/covid-19-resources/ 
LSTM: COVID-19 
https://www.lstmed.ac.uk/covid-19 
LSHTM: COVID-19 
https://www.lshtm.ac.uk/research/research-action/covid-19 
International Disability Alliance: COVID 19 and the disability movement 
http://www.internationaldisabilityalliance.org/content/covid-19-and-disability-movement 
Africa Centres for Disease Control and Prevention (Africa CDC) 
https://africacdc.org/covid-19/ 
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UNICEF: Latest news and updates on coronavirus disease 2019 (COVID-19) 
https://www.unicef.org/coronavirus/covid-19 
Coronavirus: the science explained 
https://coronavirusexplained.ukri.org/en/ 
Social Science in Humanitarian Action: Updates on the novel COVID-19 outbreak 
https://www.socialscienceinaction.org/update-novel-covid-19-outbreak/ 
Special Collection: Coronavirus (COVID-19): evidence relevant to critical care 
https://www.cochrane.org/news/special-collection-coronavirus-covid-19-evidence-relevant-
critical-care 
NICE UK: Rapid guidelines and evidence reviews  
https://www.nice.org.uk/covid-19 
Imperial College London MRC Centre for Global Infectious Disease Analysis COVID-19 
reports 
https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/news--wuhan-coronavirus/ 
Global research on COVID-19 
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-
coronavirus-2019-ncov 
WHO R&D Blueprint 
https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus/en/ 
Latest information and advice from the UK Government 
https://www.gov.uk/guidance/coronavirus-covid-19-information-for-the-public 
CDC COVID-19 Resources 
https://www.cdc.gov/coronavirus/2019-ncov/index.htmlThe Global Health Network Coronavirus 
outbreak knowledge hub 
The Lancet COVID-19 Resource Centre 
https://www.thelancet.com/coronavirus 
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Elsevier’s Novel Coronavirus Information Center 
https://www.elsevier.com/connect/coronavirus-information-center 
Cell Press Coronavirus Resource Hub 
https://www.cell.com/2019-nCOV 
Cochrane Special Collections - COVID-19: infection control and prevention measures 
https://www.cochranelibrary.com/collections/doi/SC000040/full 
The BMJ Coronavirus (covid-19): Latest news and resources 
https://www.bmj.com/coronavirus?int_source=wisepops&int_medium=wisepops&int_campaign=
DAA_CoronaVirus_Jan24 
Johns Hopkins Coronavirus Resource Centre 
https://coronavirus.jhu.edu 
Global Partnership for Sustainable Development – COVID-19 resources 
http://www.data4sdgs.org/resources/covid-19-resources 
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